Overall, this study has revealed a novel regulatory connection between miR-181a and SERPINE1 in CML stem/progenitor cells and provided new pieces of evidence to promote the combination therapy of SERPINE1 inhibitors and TKIs in CML treatment. The gene discussed is SERPINE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.